Home » Stocks » IMGN

ImmunoGen, Inc. (IMGN)

Stock Price: $8.69 USD -0.38 (-4.19%)
Updated Mar 3, 2021 4:00 PM EST - Market closed
After-hours: $8.61 -0.08 (-0.92%) Mar 3, 7:16 PM
Market Cap 1.69B
Revenue (ttm) 132.30M
Net Income (ttm) -44.37M
Shares Out 176.15M
EPS (ttm) -0.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 3
Last Price $8.69
Previous Close $9.07
Change ($) -0.38
Change (%) -4.19%
Day's Open 9.12
Day's Range 8.69 - 9.17
Day's Volume 2,341,504
52-Week Range 1.95 - 10.88

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 2 days ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire - 1 week ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference

Zacks Investment Research - 2 weeks ago

ImmunoGen (IMGN) reports encouraging fourth-quarter results. Top-line data readout from pivotal studies on its lead candidate, mirvetuximab soravtansine, remains on track.

The Motley Fool - 2 weeks ago

The company can thank its partner, Jazz Pharmaceuticals.

Benzinga - 2 weeks ago

Shares of Immunogen (NASDAQ:IMGN) moved higher by 2.9% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 433.33% year over year to $0....

Zacks Investment Research - 2 weeks ago

ImmunoGen (IMGN) delivered earnings and revenue surprises of 500.00% and 69.54%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 2 weeks ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and 2020 Financial Results

Business Wire - 2 weeks ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming SVB Leerink 10th Annual Global Healthcare Conference

Benzinga - 2 weeks ago

Immunogen (NASDAQ:IMGN) announces its next round of earnings this Friday, February 12. Here is Benzinga's everything-that-matters guide for this Friday's Q4 earnings announcement.

Zacks Investment Research - 3 weeks ago

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 1 month ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire - 1 month ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its 2020 Operating Results

Business Wire - 1 month ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire - 2 months ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation and Q&A at the 39th Annual J.P. Morgan Healthcare Conference

Seeking Alpha - 2 months ago

ImmunoGen: Update On A Turnaround Story

Zacks Investment Research - 2 months ago

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock?

Business Wire - 2 months ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting

Business Wire - 3 months ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire - 3 months ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Recent Updates for IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukemia

Business Wire - 3 months ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcasts of Presentations at Upcoming Virtual Conferences

Zacks Investment Research - 3 months ago

ImmunoGen (IMGN) reports encouraging third-quarter results. Top-line data readout from pivotal studies on its lead candidate, mirvetuximab soravtansine, remains on track.

Seeking Alpha - 3 months ago

ImmunoGen, Inc. (IMGN) CEO Mark Enyedy on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

ImmunoGen (IMGN) delivered earnings and revenue surprises of 35.00% and 24.65%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 3 months ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and Third Quarter 2020 Financial Results

Business Wire - 3 months ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual London Healthcare Conference

Business Wire - 4 months ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research - 4 months ago

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 4 months ago

India's Gland Pharma, a majority-owned subsidiary of Shanghai Fosun Pharma, was approved for an $814 million IPO on India's Sebi exchange. Huadong Medicine in-licensed greater China rights to ...

Business Wire - 4 months ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2020 Operating Results

Zacks Investment Research - 4 months ago

ImmunoGen (IMGN) grants exclusive rights to Huadong Medicine for development and commercialization of mirvetuximab soravtansine in Greater China.

Business Wire - 4 months ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China

Business Wire - 4 months ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Raises $54.8 Million in Gross Proceeds Through its At-the-Market Facility

Zacks Investment Research - 4 months ago

The FDA bestows a Breakthrough Therapy status on ImmunoGen's (IMGN) IMGN632 for treating patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm. Shares rise.

24/7 Wall Street - 4 months ago

ImmunoGen Inc. (NASDAQ: IMGN) shares pushed higher to start out the week when the U.S.

Business Wire - 4 months ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

Business Wire - 5 months ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire - 5 months ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Final Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab in Combination with Carboplatin and AvastinĀ® at ESMO

Business Wire - 6 months ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming H.C.

Zacks Investment Research - 6 months ago

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 6 months ago

ImmunoGen is a turnaround stock that has tremendous potential. After temporary regulatory and clinical setbacks, the company is on a vigorous campaign for a change.

24/7 Wall Street - 6 months ago

The second half of 2020 is well underway, and with markets recovering, one of the strongest industries leading the charge has been biotech.

Other stocks mentioned: DVAX, IBB, LXRX, VKTX, XNCR
Zacks Investment Research - 7 months ago

ImmunoGen (IMGN) reports encouraging second-quarter results. Top-line data from pivotal study on its lead candidate, mirvetuximab soravtansine, likely to be delayed by six to eight weeks.

Seeking Alpha - 7 months ago

ImmunoGen, Inc. (IMGN) CEO Mark Enyedy on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

ImmunoGen (IMGN) delivered earnings and revenue surprises of 22.22% and 5.13%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 7 months ago

Shares of Immunogen (NASDAQ:IMGN) moved higher by 3.0% in pre-market trading after the company reported Q2 results.

Business Wire - 7 months ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and Second Quarter 2020 Financial Results

Business Wire - 7 months ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming Canaccord Genuity Virtual Growth Conference

Zacks Investment Research - 7 months ago

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 7 months ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Appoints Susan Altschuller, PhD as Senior Vice President and Chief Financial Officer

Business Wire - 7 months ago

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2020 Operating Results

About IMGN

ImmunoGen, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. I... [Read more...]

Industry
Biotechnology
IPO Date
Nov 16, 1989
CEO
Mark Enyedy
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
IMGN
Full Company Profile

Financial Performance

In 2020, ImmunoGen's revenue was $132.30 million, an increase of 60.81% compared to the previous year's $82.27 million. Losses were -$44.37 million, -57.39% less than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for ImmunoGen stock is "Buy." The 12-month stock price forecast is 9.94, which is an increase of 14.38% from the latest price.

Price Target
$9.94
(14.38% upside)
Analyst Consensus: Buy